Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,711
  • Shares Outstanding, K 26,396
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,430 K
  • 60-Month Beta 0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.69
Trade IMMX with:

Options Overview Details

View History
  • Implied Volatility 251.41% ( -133.15%)
  • Historical Volatility 80.07%
  • IV Percentile 18%
  • IV Rank 36.45%
  • IV High 621.29% on 02/14/24
  • IV Low 39.29% on 02/05/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 226
  • Open Int (30-Day) 236

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.94 +14.43%
on 04/22/24
3.35 -33.79%
on 03/25/24
-1.07 (-32.52%)
since 03/22/24
3-Month
1.94 +14.43%
on 04/22/24
4.64 -52.10%
on 01/25/24
-2.46 (-52.56%)
since 01/24/24
52-Week
1.40 +58.57%
on 05/26/23
7.75 -71.35%
on 12/18/23
+0.43 (+24.02%)
since 04/24/23

Most Recent Stories

More News
Stocks Set to Open Higher as Investors Await FOMC Minutes, U.S. Debt-Ceiling Talks in Focus

June S&P 500 futures (ESM23) are up +0.09%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.12% this morning as market participants continued to monitor U.S. debt-ceiling negotiations while awaiting...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
RYA.I.DX : 20.510 (-1.82%)
NWG.L.EB : 285.600 (+0.11%)
MU : 110.80 (-1.48%)
IMMX : 2.22 (-3.48%)
CTLT : 56.04 (+0.02%)
NKE : 94.66 (+0.68%)
CNI : 123.97 (-4.20%)
DKNG : 41.22 (+0.02%)
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA...

IMMX : 2.22 (-3.48%)
Immix Biopharma Announces Share Repurchase Program

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company...

IMMX : 2.22 (-3.48%)
ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities...

IMMX : 2.22 (-3.48%)
Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross...

IMMX : 2.22 (-3.48%)
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022

LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering...

IMMX : 2.22 (-3.48%)
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned...

IMMX : 2.22 (-3.48%)
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale

IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and...

IMMX : 2.22 (-3.48%)
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice...

IMMX : 2.22 (-3.48%)
Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company...

IMMX : 2.22 (-3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 2.68
2nd Resistance Point 2.51
1st Resistance Point 2.41
Last Price 2.22
1st Support Level 2.14
2nd Support Level 1.97
3rd Support Level 1.87

See More

52-Week High 7.75
Fibonacci 61.8% 5.32
Fibonacci 50% 4.57
Fibonacci 38.2% 3.83
Last Price 2.22
52-Week Low 1.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar